Bortezomib for previously untreated mantle cell lymphoma

  • Technology appraisal guidance
  • TA370
  • Published: 

History

Documents created during the development process.

Invitation to participate

Final appraisal determination

Lymphoma (mantle cell, untreated) - bortezomib [ID724]: equality impact assessment - scoping

Lymphoma (mantle cell, untreated) - bortezomib [ID724]: : NICE response to comments on the draft scope and provisional matrix

Lymphoma (mantle cell, untreated) - bortezomib [ID724]: final matrix

Lymphoma (mantle cell, untreated) - bortezomib [ID724]: final scope

Lymphoma (mantle cell, untreated) - bortezomib [ID724]: draft scope (pre-referral) - June 2014

Lymphoma (mantle cell, untreated) - bortezomib [ID724]: provisional matrix (pre-referral) - June 2014